Australia became the first country to allow authorized prescribing of MDMA for PTSD outside clinical trials. Interviews with 21 clinicians, researchers, and patients who had direct experience with MDMA-assisted psychotherapy or PTSD revealed eleven themes, including the importance of expectation management, comprehensive baseline screening, shared decision-making, flexible treatment protocols, ongoing consent, strong therapeutic alliance, and post-treatment continuity of care. The findings emphasize the need for safeguards, provider training, and integration of care as MDMA-assisted psychotherapy enters clinical practice.
Clinical guidelines and position statements from multiple countries recommend medical psilocybin-assisted psychotherapy for adults with depression, but they vary in their specific conditions and safeguards. The review of international documents shows consensus that PAP should be administered in controlled clinical settings with trained therapists, though recommendations differ on patient selection criteria, dosing protocols, and integration procedures. Most guidelines emphasize the need for further research to establish long-term safety and efficacy.